Abstract

**Background**
It is reported that postoperative nausea and vomiting, common general anesthesia complications, may be prevented by perioperative intravenous dextrose administration, but with controversial clinical effectiveness.

**Objective**
To evaluate perioperative intravenous dextrose for preventing postoperative nausea and vomiting through a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.

**Data sources**
MEDLINE, the Cochrane Central Register of Controlled Trials, Embase, Web of Science, clinicaltrials.gov, and the University Hospital Medical Information Network Clinical Trials Registry were searched from inception until 22 June 2019.

**Eligibility criteria**
Trials investigating intravenous dextrose effects vs. placebos on postoperative nausea and vomiting in patients who underwent general anesthesia.

**Results**
Eleven trials (1,250 patients) were included. All participants were ASA1-2. The nine trials included laparoscopic surgeries, and 92.2% of the participants were women. The timing of dextrose infusion was before, during, and after surgery in three, five, and three trials, respectively. Our results revealed intravenous dextrose administration significantly reduced
postoperative nausea, but not vomiting, during early and late postoperative periods (risk ratio [95% confidence interval], early nausea: 0.76 [0.59–0.99], late nausea: 0.65 [0.48–0.89]; early vomiting: 1.00 [0.81–1.25], late vomiting: 0.96 [0.43–2.16]). Evidence quality was downgraded to low because the trial sequential analysis indicated more trials are needed for firm conclusions.

**Conclusions**

Compared with placebos, perioperative intravenous dextrose administration may decrease postoperative nausea but not vomiting.

**Trial registration**

University Hospital Medical Information Network Clinical Trials Registry (registration number: UMIN000030901).

---

**Introduction**

Postoperative nausea and vomiting (PONV) are common complications associated with general anesthesia with an incidence of approximately 80% in a subset of high-risk patients. [1] PONV is a leading cause of aspiration pneumonia, dehydration, electrolyte imbalance, and patient dissatisfaction. Unresolved PONV may result in a prolonged hospital stay, unanticipated admissions, and prolonged nursing care. [2] Therefore, PONV prevention is important not only for improving patient safety, but also for reducing medical costs.

There are several pharmacological PONV prophylactic strategies, such as serotonin 5-HT₃ receptor antagonists, dexamethasone, or droperidol administration. [1] However, these approaches implicate potential side effects and extra cost. For example, serotonin 5-HT₃ receptor antagonists reduce PONV incidence, [3,4] but increase the incidence of arrhythmia, [5] headaches, [6] or dizziness. [7] Furthermore, serotonin 5-HT₃ receptor antagonists are relatively expensive, thereby increasing treatment costs.

Intravenous dextrose administration may prevent PONV as it reduces insulin resistance and decreases gastric acid secretion, [8,9] which may contribute to PONV. Several studies have reported that perioperative dextrose administration decreases PONV, but its efficacy is controversial. [10–12] Therefore, we conducted a systematic review and meta-analysis to elucidate the effects of perioperative intravenous dextrose on PONV prevention.

**Methods**

This study was a systematic review and meta-analysis with trial sequential analysis (TSA).

We followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and the Cochrane Handbook. [13,14] Our study protocol and analysis methods were prespecified and registered in the University Hospital Medical Information Network Clinical Trials Registry (registration number: UMIN000030901).

**Search strategy**

The literature databases MEDLINE, Cochrane Register of Controlled Trials, Embase, and Web of Science were searched without language restrictions. Further, we endeavored to identify ongoing studies from clinicaltrials.gov and the University Hospital Medical Information
Network Clinical Trials database. The reference lists of the retrieved full articles were also searched. The search strategy combining free text and Medical Subject Headings terms for PubMed is described in S1 File. The database search was conducted on June 22, 2019. All records were searched from database inception.

Two authors (CY and SK) independently scanned titles and abstracts of reports identified using the search strategies described above. If eligibility could not be determined from the title or abstract, the full paper was retrieved. Potentially relevant studies were retrieved and full-text versions were evaluated. Articles that met the inclusion criteria, described below, were assessed separately by the 2 authors, and any discrepancies were resolved through discussion.

Inclusion and exclusion criteria
We searched for all randomized controlled trials (RCTs) that tested the effects of intravenous dextrose compared with a placebo on postoperative nausea (PON) and/or postoperative vomiting (POV). We excluded case reports, comments, reviews, and animal studies. We excluded studies that did not include fluid administration control groups, considering it is difficult to differentiate the effect of fluid administration and dextrose infusion in such trials. If a study included more than one control group, we only included the data of the control group with fluid administration. Eligibility was not restricted by surgery type, anesthetic technique, or patient age.

Primary and secondary outcomes
The primary outcome of this meta-analysis was the incidence of PON/POV during the early postoperative period (defined below). The secondary outcomes were the incidence of PON/POV during the late postoperative period, the need for rescue antiemetics, hyperglycemia incidence, and postoperative blood glucose levels. The definitions of early and late postoperative periods are described below. If the primary outcomes were missing in the article, we contacted the corresponding authors for clarification. The pre-specified primary and secondary outcomes were modified. The modification details are described in the supplementary information (S1 File).

Data collection
A data collection sheet was created and included data on the number of patients in study; patient age; patient sex; patient American Society of Anesthesiologists physical status classification; type of anesthesia; surgery type; dextrose dose; incidence of PON and POV during the early and late postoperative periods; number of rescue antiemetics used within 24 hours after surgery; side effects (blood glucose level, hunger, and thirst); and funding information. Data of the early and late periods of the first postoperative 24 hours were collected separately. When the first postoperative 24 hours were divided into 2 time periods (e.g., 0–6 and 6–24 hours), the first time period was defined as the early period and the second time period as the late period. When the first postoperative 24 hours were divided into more than 2 time periods, the data representing postoperative hours 1–2 and 24 hours were defined as the early and late periods, respectively. Values originally provided as percentages were converted into actual patient numbers for analysis. Two authors (CY and MK) extracted the data independently from the studies included, then cross-checked the data. Disagreements were resolved by discussion between the 2 authors.
Assessment of risk of bias in individual studies

The risk of bias was assessed as described by the Cochrane Handbook for Systematic Reviews of Interventions. [14] The risk of bias was evaluated in sequence generation; allocation sequence concealment; blinding of patients, health care providers, data collectors, and outcome assessors; incomplete outcome data; selective outcome reporting; and other bias.

The risk of bias was classified as "low", "high", or "unclear". Two authors (CY and MK) evaluated the risk of bias independently. The risk of bias summary was categorized as "low" for RCTs with a low risk of bias in all domains, "high" for RCTs with a high risk of bias in at least 1 domain, and "unclear" for RCTs that were neither "low" nor "high" in the risk of bias.

Assessment of quality of evidence

The quality of evidence for the main outcomes was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach with GRADEpro software. [15] Evidence quality was judged based on the presence or absence of the following variables: limitations in study design, inconsistency, indirectness, imprecision of the results, and publication bias. The quality of evidence for the main outcomes was graded as very low, low, moderate, or high.

Statistical analysis

Continuous data were summarized using the mean difference (MD) with a 95% confidence interval (CI). Dichotomous data were summarized using a risk ratio (RR) with a 95% CI. If the 95% CI included a value of 0 or 1 for continuous or dichotomous data, respectively, the difference was not considered statistically significant. We used a random-effects model (DerSimonian and Laird methods [16]) to combine the results of the studies. When the number of studies was small (i.e., <10), we used the Hartung-Knapp-Sidik-Jonkman adjustment [17] for the random-effects meta-analysis. Heterogeneity was quantified with the I² statistic; significant heterogeneity was considered to exist when the I² statistic exceeded 50%. The cause of statistical heterogeneity was explored via a subgroup analysis according to the following predefined factors when the I² statistic exceeded 50%: (1) presence or absence of prophylactic antiemetics, (2) dextrose dose (more or less than 250 ml of 5% dextrose), or (3) surgery type. Forest plots were used to graphically represent and evaluate the effects of treatment. Small-study effects, assessed using a funnel plot and an Egger’s regression asymmetry test, [18] were considered positive if \( P < 0.1 \) in the regression asymmetry test. Sensitivity analyses were performed for the incidence of PON/POV according to the risk of bias, in which RCTs with a high risk of bias or published in abstract form only were excluded. For statistically significant differences in outcomes, the number needed to treat (NNT) was calculated to estimate the overall clinical impact of the intervention.

For the incidence of PON/POV, TSA was performed to correct for random error and repetitive testing of accumulating and sparse data. [19–22] TSA monitoring boundaries and required information size (RIS) were quantified, and adjusted CIs were calculated. The RIS should be regarded as a target sample size for a meta-analysis. The risk of a type 1 error was maintained at 5% with 90% power. We used diversity (D²) [23] as an estimator of heterogeneity for the RIS calculation. The RR of 0.75 for PONV incidence (i.e., 25% relative risk reduction) was considered clinically meaningful. If the TSA-adjusted CI included a value of 1, the evidence quality was downgraded for the outcome due to the imprecision of the results.

Statistical analyses were performed using the R statistical software package, version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria). TSA was performed using TSA viewer version 0.9.5.9 β (www.ctu.dk/tsa).
Results

A comprehensive search of the 6 databases produced 495 citations. The full texts of 23 articles were examined in detail. Twelve articles were excluded (S1 File) because they did not meet the inclusion criteria. Eleven articles with 1,250 patients were included in this meta-analysis (Fig 1). Of the 11 articles, 10 were in English, and 1 was in Korean.

The features of the 11 RCTs are presented in Table 1. The participants were only women in 6 RCTs [11,12,24,27–29], and 92.2% of the participants in this meta-analysis were women. All participants included were ASA1–2. Table 1 presents the mean age of participants in each trial. The type of surgery in 9 RCTs was laparoscopic surgery. [10,12,24,25,27–31] In 8 RCTs, [12,24–29,31] the dextrose dose was > 12.5 g. In 3 RCTs, [10,12,31] prophylactic antiemetics were administered. One RCT [25] was an abstract-only publication. When the primary outcomes were missing in the article, we contacted the corresponding authors for clarification. However, we received no response.

Risk of bias

The risk of bias in the included trials is summarized in Table 2. No RCT was considered to have a low risk of bias, 3 RCTs were considered to have a high risk of bias, [25,26,28] and the rest had an unclear risk of bias. The details on each evaluation were reported in the S1 File. The GRADE table with full details are presented in S1 Table.

Early PON

Nine RCTs (10 comparisons) with 919 patients were analyzed for the effects of intravenous dextrose on the prevention of early PON. [10–12,24–26,29–31] Combined results showed that the incidence of early PON was significantly lower in the dextrose group than in the control group (RR [95% CI] = 0.76 [0.59 to 0.99], $I^2 = 28\%$, NNT [95% CI] = 15 [9 to 292], Fig 2A). A sensitivity analysis according to the risk of bias did not change the direction of dextrose effects on early PON prevention (RR [95% CI] = 0.84 [0.52 to 1.35], $I^2 = 9.4\%$). The Z-curve did not cross the TSA monitoring boundary (Fig 2B). The TSA-adjusted CI was 0.51–1.14 and the TSA revealed that the accrued information size (n = 919) was 49.0% of the RIS (n = 1877). A small-study effect was not detected using the regression test for funnel plot asymmetry ($P = 0.11$, S1A Fig). The evidence quality was downgraded to low due to the lack of precision and high risk of bias. The GRADE table with full details are presented in S1 Table.

Early POV

Eight RCTs with 819 patients were analyzed for the intravenous dextrose effects on early POV prevention. [11,12,24–26,29–31] Combined results showed that the incidence of early POV did not significantly differ between the dextrose and control groups (RR [95% CI] = 1.00 [0.81 to 1.25], $I^2 = 0\%$, Fig 3). A sensitivity analysis according to the risk of bias did not change the results (RR [95% CI] = 1.13 [0.56 to 2.28]). The Z-curve did not cross the TSA monitoring boundary (S2 Fig); the TSA-adjusted CI was 0.14 to 7.49. TSA revealed that the accrued information size (n = 819) was only 9.8% of the RIS (n = 8321). A small-study effect was not detected with the regression test for funnel plot asymmetry ($P = 0.92$, S1B Fig). The quality of evidence was downgraded to low due to the lack of precision and the very small size of accrued information (S1 Table).

Late PON

Eight RCTs with 857 patients were analyzed for the intravenous dextrose effects on preventing late PON. [10,11,24–26,29–31] Combined results revealed that the incidence of late PON was
| Study                          | Total number of patients | ASA-PS | Mean Age | Sex (M/F) | Surgery                      | Timing of administration | Dose of dextrose | Volume of dextrose | Length of infusion | Control fluid                  | Control Volume | Baseline antiemetics |
|-------------------------------|--------------------------|--------|----------|-----------|------------------------------|--------------------------|-------------------|-------------------|-------------------|--------------------------|----------------|---------------------|
| Dabu-Bondoc 2013 [12]         | 62                       | 1–2    | 37.5 (9.8) | 0/62      | Gynecologic laparoscopic and hysteroscopic procedures | After surgery            | 50 g              | 1000 mL           | > 30 min          | Ringer’s lactate solution  | 1000 mL        | Ondansetron           |
| Mishra 2017 [10]              | 100                      | 1–2    | 39.6 (11.5) | 28/72     | Laparoscopic cholecystectomy | continuously during gallbladder removal | 12.5 g             | 250 ml            | From gallbladder removal to fluid finish | normal saline | 250 mL               | Dexamethasone       |
| Patel 2013 [11]               | 162                      | 1–2    | 45.5 (1.25) | 0/162     | Gynecologic, urologic, or breast surgery | Beginning with the start of surgical closure | 12.5 g             | 250 ml            | 2 hours           | Ringer’s lactate solution  | 250 mL        | None                 |
| Conan McCaul 2003 [24]        | 120                      | 1      | 32.3 (5.0)  | 0/120     | Elective gynecological laparoscopy | At the induction of anesthesia | 32 ± 5.8 g         | 1,148 ± 210 mL    | 20 min            | CSL 1.5 mL/kg, no iv fluid | 1,115 ± 363 mL | None                 |
| Firouzian 2017 [28]           | 150                      | 1–2    | 41.4 (12.8) | 0/150     | Laparoscopic cholecystectomy | 30 min before induction of anesthesia | 25 g               | 500 ml            | 30 minutes        | Ringer’s lactate solution  | 500 ml        | None                 |
| Shin 2007 [26]                | 160                      | 1–2    | 37.5 (14.7) | 46/78     | Not reported                  | Before anesthesia         | 0.1 g/kg/hr, 1 g/kg/hr | 2 mL/kg, 20 mL/kg | 30 minutes        | Hartmann’s solution | 2 mL/kg, 20 mL/kg | Not reported |
| Rao 2017 [31]                 | 115                      | 1–2    | 43 (13)    | 4/111     | Laparoscopic cholecystectomy | At the PACU               | 50 g               | 1000 mL           | Within 30–40 minutes | lactated Ringer’s solution | 1000 mL        | Ondansetron           |
| Cook 1990 [29]                | 75                       | 1–2    | 31.4 (6.5)  | 0/75      | Elective laparoscopic surgery | Before surgery            | 1 g/kg             | 20 mL/kg          | 45 minutes        | no peri-operative fluid, 20 mL/kg compound sodium lactate solution | 20 mL/kg       | Not reported          |
| Atashkhoei 2018 [27]          | 70                       | 1      | 32.1 (1.0)  | 0/70      | Diagnostic laparoscopy for infertility | 5 minutes before the induction of anesthesia | 500 mg/kg           | 10 mL/kg/hr       | From 5 minutes before inducing anesthesia to the end of operation | Ringer’s solution with normal saline 0.9% | 10 mL/kg/hr | Not reported          |
| Jain 2016 [25]                | 150                      | 1–2    | Not reported | Not reported | Laparoscopic cholecystectomy | After surgery in the PACU | 50 g               | 1000 mL           | 30–40 minutes     | Ringer Lactate       | 1000 mL        | Not reported          |
| Pin On 2018 [30]              | 86                       | 1–2    | 39.3 (10.7) | 0/86      | Gynecologic laparoscopy      | During the anesthesia maintenance | unknown           | 2 mL/kg/hr        | unknown           | normal saline solution       | 2 mL/kg/hr    | Not reported          |

ASA-PS, American Society of Anesthesiologists physical status; F, female; M, male; ACU, post-anesthesia care unit; SD, standard deviation

https://doi.org/10.1371/journal.pone.0231958.t001
significantly lower in the dextrose group than in the control group (RR [95% CI] = 0.65 [0.48 to 0.89], I² = 0%, NNT [95% CI] = 31 [21 to 99], Fig 4). A sensitivity analysis according to the risk of bias did not change the direction of the dextrose effects on preventing late PON (RR [95% CI] = 0.62 [0.22 to 1.81]).

The Z-curve did not cross the TSA monitoring boundary (S3 Fig); the TSA-adjusted CI was 0.11 to 3.94. TSA showed that the accrued information size (n = 857) was only 12.5% of the RIS (n = 6838). A small-study effect was not detected using the regression test for funnel plot asymmetry (P = 0.76, S1C Fig). The quality of evidence was downgraded to low due to the lack of precision and the very small size of accrued information (S1 Table).
Late POV

Seven RCTs with 757 patients were analyzed for the intravenous dextrose effects on preventing late POV. [11,24–26,29–31] Combined results revealed that the incidence of late POV did not differ between the dextrose and control groups (RR [95% CI] = 0.96 [0.43 to 2.16], I² = 0%, Fig 5).

A sensitivity analysis according to the risk of bias did not change the results (RR [95% CI] = 0.78 [0.02 to 24.5]). A TSA boundary could not be calculated due to insufficient information (3.4% of the RIS).

A small-study effect was not detected using the regression test for funnel plot asymmetry (P = 0.51, S1D Fig). The quality of evidence was downgraded to low due to lack of precision and the small size of accrued information (S1 Table).

Rescue use

Eight RCTs with 750 patients were analyzed for the intravenous dextrose effects on the incidence of early rescue use. [10–12,24,27–29,31] Combined results revealed that the incidence of early rescue use did not differ between the dextrose and control groups, with high heterogeneity (RR [95% CI] = 0.70 [0.44 to 1.12], I² = 70%, S4A Fig). A small-study effect was not detected with the regression test for funnel plot asymmetry (P = 0.14).

To explore the causes of heterogeneity, a prespecified subgroup analysis was conducted according to the dose of dextrose (more or less than 12.5 g). The incidence of early rescue use was not reduced in either high or low dose dextrose (RR [95% CI] = 0.65 [0.38 to 1.13], I² = 40% and 0.71 [0.001 to 378], I² = 91%, respectively, S4A Fig). The P value of the test for subgroup differences was 0.94. An analysis of the other prespecified subgroup was not conducted because the presence or absence of prophylactic antiemetics was not reported in 5 of 11 RCTs and only 1 RCT examined non-laparoscopic surgery.

Two RCTs with 186 patients were analyzed for the effects of intravenous dextrose on the incidence of late rescue use. [24,31] Combined results showed that the incidence of late rescue did not differ between the dextrose and control groups (RR [95% CI] = 0.90 [0.001 to 1315],
### Intravenous dextrose for postoperative nausea prevention

#### Table: Effect of dextrose on postoperative nausea

| Study          | Dextrose Events | Dextrose Total | Control Events | Control Total | Risk Ratio | RR    | 95% CI         |
|----------------|----------------|---------------|----------------|---------------|------------|-------|----------------|
| Dabu-Bondoc 2013 | 14             | 30            | 20             | 32            | 0.75       | 0.47  | 1.19           |
| Mishra 2017     | 6              | 50            | 14             | 50            | 0.43       | 0.18  | 1.03           |
| Patel 2013      | 9              | 87            | 7              | 75            | 1.11       | 0.43  | 2.83           |
| Conan McCaul 2003 | 6             | 35            | 4              | 36            | 1.54       | 0.48  | 5.00           |
| Shin 2007       | 9              | 27            | 10             | 36            | 1.20       | 0.57  | 2.54           |
| Shin 2007       | 5              | 26            | 4              | 35            | 1.68       | 0.50  | 5.66           |
| Rao 2017        | 17             | 56            | 32             | 59            | 0.56       | 0.35  | 0.89           |
| Cook 1990       | 12             | 25            | 11             | 24            | 1.05       | 0.58  | 1.90           |
| Jain 2013       | 23             | 75            | 43             | 75            | 0.53       | 0.36  | 0.79           |
| Pin On 2016     | 2              | 42            | 2              | 44            | 1.05       | 0.15  | 7.10           |

**Random effects model**

Heterogeneity: $I^2 = 28\%$

#### Cumulative Z-Score

- **RIS = 1877**
- **Number of patients (Linear scaled)**

---

**PLOS ONE** | https://doi.org/10.1371/journal.pone.0231958  
April 20, 2020  
9 / 17
I² = 0%, S4B Fig). An asymmetry test could not be performed for the funnel plot because only 2 trials were included.

**Side effects**

Six RCTs (7 comparisons) with 641 patients were analyzed for blood glucose levels after dextrose infusion. [11,26–29,31] Combined results revealed that intravenous dextrose infusions were associated with increased blood glucose levels compared to controls with high heterogeneity (MD [95% CI] = 65.9 [0.3 to 131.4] mg/dl, I² = 100%, S5A Fig). To explore the causes of heterogeneity, a prespecified subgroup analysis was performed according to the dextrose dose (more or less than 12.5 g). Low-dose intravenous dextrose led to a significant but mild increase of blood glucose levels (MD [95% CI] = 32.5 [1.97 to 62.9] mg/dl, I² = 0%, S5A Fig). High-dose intravenous dextrose did not significantly affect blood glucose levels (MD [95% CI] = 79.3 [-22.7 to 181.2] mg/dl, I² = 100%, S5A Fig). The P value of the test for subgroup differences was 0.48.

| Dextrose     | Total | Control | Risk Ratio | RR    | 95%CI  |
|--------------|-------|---------|------------|-------|--------|
| Dabu-Bondoc 2013 | 4    | 30      | 4 32       | 1.07  | [0.29; 3.89] |
| Patel 2013   | 0    | 87      | 1 75       | 0.29  | [0.01; 6.96] |
| Conan McCaul 2003 | 1    | 35      | 1 36       | 1.03  | [0.07; 15.81] |
| Shin 2007    | 1    | 27      | 1 36       | 1.33  | [0.09; 20.37] |
| Shin 2007    | 0    | 26      | 0 35       | 1.33  | [0.03; 65.09] |
| Rao 2017     | 6    | 56      | 7 59       | 0.90  | [0.32; 2.52] |
| Cook 1990    | 6    | 25      | 4 24       | 1.44  | [0.46; 4.48] |
| Jain 2016    | 8    | 75      | 9 75       | 0.89  | [0.36; 2.18] |
| Pin On 2016  | 1    | 42      | 1 44       | 1.05  | [0.07; 16.21] |

**Random effects model**

Heterogeneity:  $I^2 = 0%$

403  416

1.00 [0.81; 1.25]

Fig 3. A forest plot for the effects of intravenous dextrose on preventing postoperative vomiting during the early postoperative period. CI, confidence interval; RR, risk ratio.

https://doi.org/10.1371/journal.pone.0231958.g003
Three RCTs (4 comparisons) with 288 patients were analyzed for hunger. [26,29,31] Combined results revealed that intravenous dextrose treatments significantly reduced the incidence of hunger compared to controls (RR [95% CI] = 0.73 [0.58 to 0.92], I² = 0%, S5B Fig).

Three RCTs (4 comparisons) with 288 patients were analyzed for thirst. [26,29,31] Combined results revealed that the incidence of thirst did not differ between the treatment and control groups (RR [95% CI] = 1.28 [0.78 to 2.09], I² = 72%, S5C Fig).

Discussion

Our results indicate that intravenous dextrose administration reduces the incidence of PON, but not POV, during both the early and late postoperative periods (GRADE: low). However, the absolute reduction of the incidence of PON was small, and therefore, the NNT due to dextrose was high. Our results also suggest that intravenous dextrose increases blood glucose levels.

Intravenous dextrose administration is an approach used to prevent PON; we have shown that it reduced the incidence of early and late PON. The intravenous dextrose dose in 8 of the 11 included studies was ≥ 25 g, which is equivalent to 500 ml of 5% dextrose fluid. The administration timing was before or during surgery in 8 of the 11 included studies. However, the NNT for the effect of dextrose was high (NNT = 15 for early PON, NNT = 31 for late PON). Given that intravenous dextrose can cause hyperglycemia, it may be difficult to suggest routine administration, currently. Although the mechanisms of intravenous dextrose-mediated...
prevention of PON are not clear, we propose the following 3 hypotheses. First, high blood glucose levels due to intravenous dextrose may reduce gastric acid secretion, [32] consequently reducing gastric contractions and nausea. Firouzian et al. reported that nausea scores and blood glucose levels after post-anesthesia care unit arrival are negatively correlated. [28] Second, perioperative glucose administration may improve insulin resistance and may lead to a reduced incidence of PONV. [33–35] Third, dextrose and fluid administration may reduce pain and opioid consumption, [36] which lead to reducing PON. However, to elucidate the mechanism is out of the scope of the current review, and we cannot further examine the mechanisms with these methods. We focused on the effect of intravenous dextrose administration rather than oral intake. We considered intravenous administration to be a safe and efficient way to administer dextrose in surgical patients, especially those who cannot be orally fed. This is because all surgical patients have at least one intravenous route, all elective surgical patients are not allowed oral intake 2 hours before surgery for safety reasons, and some patients cannot orally intake medicines due to illnesses. However, since the perioperative administration of oral carbohydrates is known to reduce insulin resistance, oral glucose intake may reduce PONV. Furthermore, oral intake of dextrose is feasible in most patients undergoing laparoscopic surgery. Therefore, another systematic review for the effect of oral dextrose intake may be needed to elucidate its effect, although it is out of the scope of the current review.

Our results indicate that intravenous dextrose did not affect the incidence of POV, although it reduced the incidence of PON. One possible explanation for this discrepancy is the difference in pathogenesis between nausea and vomiting. Nausea is a subjective sensation evaluated by patients [37] and is regarded as a conscious cortical activity. [38] On the other hand, vomiting is regarded as a brainstem reflex. [38] Thus, any therapy for POV prevention should affect or modify brainstem activity. Based on our results, intravenous dextrose may not affect the brainstem though it...
likely affects cortical activity. Another possible explanation is the lack of statistical power in our meta-analysis of POV incidence. In our meta-analysis, the POV incidence in the control group was very low (6.7% and 2.6% in early and late periods, respectively). Consequently, the 95% CIs of the results were wide, precluding the ability to draw firm conclusions.

Our results show significant effects of intravenous dextrose on PON prevention, though this is inconsistent with a recent meta-analysis that reported perioperative intravenous dextrose had no significant effect on PONV reduction in the post-anesthesia care unit (RR [95% CI] = 0.91 [0.73 to 1.15], 7 RCTs with 661 patients) or within the first 24 h of surgery (RR [95% CI] = 0.76 [0.55 to 1.04]). [39] There are at least 2 possible reasons for this discrepancy. First, the recent meta-analysis assessed PON and POV together, [39] whereas we assessed PON and POV separately. As described above, the pathogenesis of nausea and vomiting differs. Notably, the recommendations for PONV research by Apfel et al. state that nausea and vomiting should be assessed separately. [38] Therefore, we assessed PON and POV separately, thereby reducing the heterogeneity of the outcomes. Second, the total sample size was larger in our study than in the recent meta-analysis. [39] We included 9 RCTs (10 comparisons) with 919 patients for analysis of early PON, whereas the recent meta-analysis included 7 RCTs with 661 patients. Thus, our larger sample size may have reduced beta errors.

The incident of early rescue use did not differ between dextrose and control groups. Subgroup analyses were conducted to elucidate the causes of heterogeneity observed in the overall analysis ($I^2 = 70\%$). However, the cause of heterogeneity was not detected because the 95% CIs were highly overlapped between the high and low dose dextrose and the $P$ value of the test for subgroup difference (i.e., interaction $P$ value) [40] was 0.94.

Hyperglycemia causes neutrophil dysfunction, decreases local immune responses at the surgical site, and increases the risk of surgical site infection (SSI). Particularly, several studies have reported that the risk of SSI increases with perioperative hyperglycemia. [41, 42] In our meta-analysis, dextrose infusion increased blood glucose levels compared with control levels. Most RCTs showed a mild increase in blood glucose levels, but 2 RCTs using $\geq 50$ g of dextrose reported blood glucose levels over 200 mg/dl after the intervention. [26, 31] Although the incidence of SSI was not reported in all included RCTs, the results should be interpreted with caution because the majority of these studies excluded patients with diabetes mellitus. In the subgroup analysis, high-dose intravenous dextrose did not significantly increase blood glucose levels, whereas low-dose intravenous dextrose increased blood glucose levels significantly. Interpretation should be applied cautiously because the test for subgroup difference was not significant (interaction $P$-value = 0.48). Furthermore, the point estimate of the increase in blood glucose level was higher in the high-dose group.

Our meta-analysis has several limitations. First, the TSA indicated that the total sample size included in our meta-analyses was insufficient to draw firm conclusions. The Z-curve did not cross the TSA-monitoring boundaries in our primary outcome. Second, the incidence of PONV in the control group was low in our meta-analysis, especially in early POV and late POV, which may lead to a lack of statistical power. Thirdly, we modified the pre-specified primary outcome; this is a major limitation of this study. The pre-specified primary outcome was the incidence of PONV during postoperative 24 hours. Fourth, the trials included in our meta-analysis included only ASA1-2 patients and the majority of these studies excluded patients with diabetes mellitus. Further, patients with gastric paresis may not have been included in all studies. Therefore, our results can not apply to critically ill patients or patients with diabetes mellitus. Fifth, there was no RCT that had a low risk of bias. Therefore, we downgraded the evidence quality. We contacted authors to resolve unclear points regarding the risk of bias assessment, but we received no response. Sixth, heterogeneity was found in early rescue use, blood glucose level, and thirst. The cause of heterogeneity was not detected in our pre-specified
subgroup analyses. Seventh, there were two RCTs [25,31] whose results in the Forrest plot were similar, and we could not firmly assess if the study population was overlapping between the two RCTs. We asked the authors if the same data were used in two articles, but received no response. We included two RCTs in our meta-analysis and confirmed that the sensitivity analysis, excluding the one RCT [25] with a high risk of bias, did not change the result.

In conclusion, perioperative intravenous dextrose administration may decrease the incidence of PON but not POV (GRADE: low). The incidence of early rescue antiemetics use did not differ between the dextrose and control groups.

**Supporting information**

S1 Checklist. Checklist of items to include when reporting a systematic review or meta-analysis.

(SDOC)

S1 File. Supplemental digital content 1.

(ODOCX)

S1 Fig. Funnel plots for early/late PON/POV. PON, postoperative nausea; POV, postoperative vomiting.

(TIF)

S2 Fig. Trial sequential analysis for the effects of intravenous dextrose on preventing postoperative vomiting during the early postoperative period. The blue line is the cumulative Z-curve. The curved red lines are the trial sequential analysis monitoring boundaries and the green lines are the conventional boundaries (i.e., \(P = 0.05\)) for benefit or harm. RIS, required information size.

(TIF)

S3 Fig. Trial sequential analysis for the effects of intravenous dextrose on preventing postoperative nausea during the late postoperative period. The blue line is the cumulative Z-curve. The curved red lines are the trial sequential analysis monitoring boundaries and the green lines are the conventional boundaries (i.e., \(P = 0.05\)) for benefit or harm. RIS, required information size.

(TIF)

S4 Fig. Forest plots for the effects of intravenous dextrose on rescue use. a: The results for rescue use during early time periods. b: The results for rescue use during late time periods.

(TIF)

S5 Fig. Forest plots for the side effects of intravenous dextrose. a: Results of blood glucose levels after administration. b: Results for hunger. c: Results for thirst.

(TIF)

S1 Table. The GRADE table with full details. CI: Confidence interval; GRADE: Grading of Recommendations Assessment, Development, and Evaluation; RR: Risk ratio.

(ODOCX)

**Acknowledgments**

**Assistance with this article**

We would like to thank Editage (www.editage.jp) for English language editing.
Presentation

Preliminary data for this study were presented as a poster presentation at the European Society of Anaesthesiology (ESA) Euroanaesthesia meeting, 1 June to 3 June 2019, Vienna.

Author Contributions

Conceptualization: Chisaki Yokoyama, Takahiro Mihara, Shizuka Kashiwagi, Motokazu Koga.

Data curation: Chisaki Yokoyama, Takahiro Mihara, Shizuka Kashiwagi, Motokazu Koga.

Formal analysis: Takahiro Mihara.

Methodology: Takahiro Mihara.

Supervision: Takahisa Goto.

Writing – original draft: Chisaki Yokoyama, Takahiro Mihara.

Writing – review & editing: Takahiro Mihara, Takahisa Goto.

References

1. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014; 118: 85–113. https://doi.org/10.1213/ANE.0000000000000002 PMID: 24356162

2. Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, et al. Society for ambulatory anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2007; 105: 1615–1628. https://doi.org/10.1213/01.ane.0000295230.55439.f4 PMID: 18042859

3. Tang DH, Malone DC. A network meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis. Clin Ther. 2012; 34: 282–294. https://doi.org/10.1016/j.clinthera.2012.01.007 PMID: 22296947

4. Mihara T, Tojo K, Uchimoto K, Morita S, Goto T. Reevaluation of the effectiveness of ramosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Anesth Analg. 2013; 117: 329–339. https://doi.org/10.1213/ANE.0b013e31829847a1 PMID: 23757469

5. Tricco AC, Soobiah C, Antony J, Hemmelgarn B, Moher D, Hutton B, et al. Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med. 2015; 13: 142. https://doi.org/10.1186/s12916-015-0379-3 PMID: 26084332

6. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology. 1997; 87: 1277–1289. https://doi.org/10.1097/00000542-199712000-00004 PMID: 9416710

7. Yokoi A, Mihara T, Ka K, Goto T. Comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting: an updated systematic review and meta-analysis with trial sequential analysis. PLoS One. 2017; 12: e0186006. https://doi.org/10.1371/journal.pone.0186006 PMID: 28977021

8. Ljungqvist O, Thorell A, Gutniak M, Höggmark T, Efendic S. Glucose infusion instead of preoperative fasting reduces postoperative insulin resistance. J Am Coll Surg. 1994; 178: 329–336. PMID: 8149032

9. Lam WF, Mascllee AA, De Boer SY, Lamers CB. Hyperglycaemia reduces gastrin-stimulated gastric acid secretion in humans. Eur J Clin Invest. 1998; 28: 826–830. https://doi.org/10.1046/j.1365-2362.1998.00362.x PMID: 9792996

10. Mishra A, Pandey RK, Sharma A, Darlong V, Punj J, Goswami Det al. Is perioperative administration of 5% dextrose effective in reducing the incidence of PONV in laparoscopic cholecystectomy?: A randomized control trial. J Clin Anesth. 2017; 40: 7–10. https://doi.org/10.1016/j.jclinane.2017.03.048 PMID: 28625451

11. Patel P, Meineke MN, Rasmussen T, Anderson DL, Brown J, Siddighi S, et al. The relationship of intravenous dextrose administration during emergence from anesthesia to postoperative nausea and vomiting: a randomized controlled trial. Anesth Analg. 2013; 117: 34–42. https://doi.org/10.1213/ANE.0b013e318292ed5f PMID: 23687231
12. Dabu-Bondoc S, Vadivelu N, Shimono C, English A, Kosarussavadi B, Dai F, et al. Intravenous dextrose administration reduces postoperative antiemetic rescue treatment requirements and postanesthesia care unit length of stay. Anesth Analg. 2013; 117: 591–596. https://doi.org/10.1213/ANE.0b013e3182458f9e PMID: 22253268

13. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264–269. https://doi.org/10.7326/0003-4819-151-4-200908180-00135 PMID: 19622511

14. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011 [cited 2018 Jan 04] Available from http://www.cochrane.org/training/cochrane-handbook.

15. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490. https://doi.org/10.1136/bmj.328.7454.1490 PMID: 15205295

16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177–188. https://doi.org/10.1016/0197-2456(86)90046-2 PMID: 3802833

17. IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 2014; 14: 25. https://doi.org/10.1186/1471-2288-14-25 PMID: 24548571

18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629–634. https://doi.org/10.1136/bmj.315.7109.629 PMID: 9310563

19. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive—trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol. 2009; 38: 287–298. https://doi.org/10.1093/ije/dyp188 PMID: 18824466

20. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008; 61: 64–75. https://doi.org/10.1016/j.jclinepi.2007.03.013 PMID: 18083463

21. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009; 38: 276–286. https://doi.org/10.1093/ije/dyn179 PMID: 18824467

22. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008; 61: 763–769. https://doi.org/10.1016/j.jclinepi.2007.10.007 PMID: 18411040

23. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009; 30: 86.

24. McCaul C, Moran C, O’Cronin D, Naughton F, Geary M, Carton E, et al. Intravenous fluid loading with or without supplementary dextrose does not prevent nausea, vomiting and pain after laparoscopy. Can J Anesth. 2003; 50: 440–444. https://doi.org/10.1007/BF03021053 PMID: 12734150

25. Jain D, Rao V, Baia L, Bharti N. Effect of postoperative intravenous dextrose administration on nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Anesth Analg. 2016; 123: 482.

26. Shin Y, Ahn H, Choi S, Lee W, Lee B. Comparison of dextrose water and Hartmann’s solution in each low and high doses for adult ambulatory anesthesia: effect on recovery from anesthesia. Korean J Anesthesiol. 2007; 52: 55–61.

27. Atashkhoei S, Naghipour B, Marandi PHH, Dehghani A, Pourfathi H. Effect of intraoperative dextrose infusion for prevention of postoperative nausea and vomiting in diagnostic gynecologic laparoscopy. Crescent J Med Biol Sci. 2018; 5: 45–49.

28. Firouzian A, Kiasari AZ, Godazande G, Baradari AG, Alipour A, Taheri A, et al. The effect of intraoperative dextrose administration for prevention of post-operative nausea and vomiting after laparoscopic cholecystectomy: a double-blind, randomised controlled trial. Indian J Anaesth. 2017; 61: 803–810. https://doi.org/10.4103/ija.IJA_420_16 PMID: 29242652

29. Cook R, Anderson S, Riseborough M, Blogg CE. Intravenous fluid load and recovery. A double-blind comparison in gynaecological patients who had day-case laparoscopy. Anaesthesia. 1990; 45: 826–830. https://doi.org/10.1111/j.1365-2044.1990.tb14563.x PMID: 2146903

30. Pin On P, Boonsi S, Kianarong S. Intraoperative intravenous dextrose administration and the incidence of nausea and vomiting after gynecologic laparoscopic surgery: a randomized double-blind controlled study. Chiang Mai Medical Journal 2018; 57: 61–69.
31. Rao V, Bala I, Jain D, Bharti N. Effect of intravenous dextrose administration on postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a randomised controlled trial. Eur J Anaesthesiol. 2017; 34: 705–707. https://doi.org/10.1097/EJA.0000000000000643 PMID: 28872580

32. Zhou SY, Lu YX, Owyang C. Gastric relaxation induced by hyperglycemia is mediated by vagal afferent pathways in the rat. Am J Physiol Gastrointest Liver Physiol. 2008; 294: 1158–1164.

33. Libiszewski M, Drozda R, Smigielski J, Kuzdak K, Kolomecki K. Preparation of patients submitted to thyroidectomy with oral glucose solutions. Pol Przegl Chir. 2012; 84: 253–257. https://doi.org/10.2478/v10035-012-0042-z PMID: 22763301

34. Bilku D, Dennison A, Hall T, Metcalfe M, Garcea G. Role of preoperative carbohydrate loading: a systematic review. Ann R Coll Surg Engl. 2014; 96: 15–22. https://doi.org/10.1308/003588414X13824511650614 PMID: 24417824

35. Smith MD, McCall J, Plank L, Herbison GP, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database Syst Rev. 2014; 8: CD009161.

36. Maharaj CH, Kallam SR, Malik A, Hassett P, Grady D, Laffey JG. Preoperative intravenous fluid therapy decreases postoperative nausea and pain in high risk patients. Anesth Analg 2005; 100: 675–682 https://doi.org/10.1213/01.ANE.0000148684.64286.36 PMID: 15728051

37. Korttila K. The study of postoperative nausea and vomiting. Br J Anaesth. 1992; 69: 20S–23S. https://doi.org/10.1093/bja/69.supplement_1.20s PMID: 1486010

38. Apfel CC, Roewer N, Korttila K. How to study postoperative nausea and vomiting. Acta Anaesthesiol Scand. 2002; 46: 921–928. https://doi.org/10.1034/j.1399-6576.2002.466082.x PMID: 12190791

39. Zorrilla-Vaca A, Marmolejo-Posso D, Stone A, Li J, Grant MC. Perioperative dextrose infusion and postoperative nausea and vomiting: a meta-analysis of randomized trials. Anesth Analg. 2019; (forthcoming).

40. Sun X, Ioannidis JPA, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users’ guide to the medical literature. JAMA. 2014; 311: 405–411. https://doi.org/10.1001/jama.2013.285063 PMID: 24449319

41. Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg. 1997; 63: 356–361. https://doi.org/10.1016/s0003-4975(96)01044-2 PMID: 9033300

42. Ramos M, Khalpey Z, lipsitz S, Steinberg J, Panizales MT, Zinner M, et al. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. Ann Surg. 2008; 248: 585–591. https://doi.org/10.1097/SLA.0b013e31818990d1 PMID: 18936571